lipid profile in schizophrenia: case control study

##plugins.themes.academic_pro.article.sidebar##

Published Jun 12, 2018
Download
pdf
Vol. 96 No. 1 (2018): Issue Jan 2018

##plugins.themes.academic_pro.article.main##

Ahmed Mhalla
Walid Bel Hadj Salah
Rim Mensi
Badii Amamou
Amal Messaoud
Leila Gassab
Wahiba Douki
Med Fadhel Najjar
Lotfi Gaha

Abstract

Introduction: Cardiovascular diseases are common co morbidities of schizophrenia and constitute the main factors of high mortality in this pathology. Cardiovascular damages are favored by some risk factors, of which one of the most important is dyslipidemia. In this context, a study of lipid profile in schizophrenia is interesting.  The aims of this study were to compare the lipid profile of patients with schizophrenia to healthy controls and to investigate the associations between lipid parameters and demographics, clinical and treatment characteristics of the patients.
Methods: We conducted a case-control study between April 2013 and March 2014 on 78 patients with schizophrenia and 68 healthy subjects who benefited from the dosage of four serum lipid parameters: total cholesterol (TC), triglycerides (TG), High-density lipoprotein Cholesterol (HDL-C) and Low-density lipoprotein cholesterol (LDL-C). For the socio-demographic and clinical assessments, we used an information sheet and the following psychometric scales: PANSS (Positive And Negative Syndrome Scale), CGI (Clinical Global Impressions), GAF (Global Assessment Functionning) and the Calgary scale for depression.
Results: The comparative study showed that serum concentrations of TC and LDL-C were significantly higher for patients compared to healthy controls respectively with (t=2,83 ; p=0,008) and             (t=9,35; p<0,001), the cholesterol ratio (TC / HDL-C) was also significantly higher for patients           (t=2,23; p=0,033). The patients had significantly higher prevalence of hypercholesterolemia              (OR = 2.96) and low density hyperlipoproteinemia (OR = 18.79). The analytical study in the population of patients showed that the age ≥35 year-old, male gender and alcohol consumption were associated with disturbances in lipid parameters. Cannabis consumption was associated with significantly lower concentrations in TG. Concerning clinical features, paranoid schizophrenia was associated with less dyslipidemia unlike the depressive dimension assessed by the Calgary scale. There was a negative correlation between plasmatic TG concentrations and doses of antipsychotics.
Conclusion: The vast majority of the literature confirms that patients with schizophrenia are at greater risk of dyslipidemia. This high risk appears to be more important with the consumption of alcohol and tobacco. It seems also that age and masculine gender are dyslipidemia risk factors for schizophrenic patients. The paranoid type of schizophrenia and positive symptoms seem to be associated with less dyslipidemia while depressive symptoms worsen lipid parameters. It then follows that, clinical and regular monitoring of lipid profile, lifestyle recommendations (smoking cessation, exercise and balanced diet) and appropriate therapeutic choices could help reduce morbidity and mortality among patients with schizophrenia. A special focus should be accorded to patients with high negative and depression symptoms.

Keywords:

schizophrenia; cholesterol; triglycerides; case control study

##plugins.themes.academic_pro.article.details##

References

  1. Liao CH, Chang CS, Wei WC, Chang SN, Liao CC, Lane HY, et al. Schizophrenia patients at higher risk of diabetes, hypertension and hyperlipidemia: a population-based study. Schizophr Res. 2011;126(1-3):110-6.
  2. WHO. The global burden of disease: 2004 update.www.who.int/healthinfo/global_burden_disease/2004_report_update/en/index.html, consultés le 8 octobre 2015.
  3. Loas G, Azi A, Noisette C, Yon V. Mortalité et causes de décès dans la schizophrénie: étude prospective entre dix et 14 ans d'une cohorte de 150 sujets. Encephale. 2008;34(1):54-60.
  4. Lefebvre N, Chéreau I, Schmitt A, Llorca PM. Comorbidités somatiques chez les patients souffrant de schizophrénie traitée. Recommandations actuelles. Ann Medico Psychol. 2006 ; 164(2):159-64.
  5. Hennekens CH, Hennekens AR, Hollar D, Casey DE. Schizophrenia and increased risks of cardiovascular disease. Am Heart J. 2005;150(6):1115-21.
  6. Parks. Morbidity and Mortality in People with Serious Mental Illness.National Association of State Mental Health Program Directors;2006.
  7. Foldemo A, Wardig R, Bachrach-Lindstrom M, Edman G, Holmberg T, Lindstrom T, et al. Health-related quality of life and metabolic risk in patients with psychosis. Schizophr Res. 2014;152(1):295-9.
  8. Austin MA, Hokanson JE, Edwards KL. Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol. 1998;81(4A):7B-12B.
  9. Chen DC, Du XD, Yin GZ, Yang K B, Nie Y, Wang N, et al. Impaired glucose tolerance in first-episode drug-naïve patients with schizophrenia: relationships with clinical phenotypes and cognitive deficits. Psychological medicine. 2016; 46(15): 3219-30.
  10. Misiak B, StaÅ„czykiewicz B, ÅaczmaÅ„ski Å, & Frydecka D. Lipid profile disturbances in antipsychotic-naive patients with first-episode non-affective psychosis: A systematic review and meta-analysis. Schizophrenia Research. 2017.
  11. Petrikis P, Tigas S, Tzallas AT, Papadopoulos I, Skapinakis P, & Mavreas V. Parameters of glucose and lipid metabolism at the fasted state in drug-naive first-episode patients with psychosis: evidence for insulin resistance. Psychiatry research. 2015; 229(3) : 901-4.
  12. Heald A, Pendlebury J, Anderson S, Narayan V, Guy M, Gibson M, et al. Lifestyle factors and the metabolic syndrome in Schizophrenia: a cross-sectional study. Annals of General Psychiatry. 2017; 16(1): 12.
  13. Szmulewicz AG, Angriman F, Pedroso F E, Vazquez C, & Martino D J. Long-Term Antipsychotic Use and Major Cardiovascular Events: A Retrospective Cohort Study. The Journal of clinical psychiatry. 2017.
  14. Citrome L, Holt RI, Walker DJ, & Hoffmann VP. Weight gain and changes in metabolic variables following olanzapine treatment in schizophrenia and bipolar disorder. Clinical drug investigation. 2011; 31(7): 455-82.
  15. Laursen TM, Munk-Olsen T, & Vestergaard M. Life expectancy and cardiovascular mortality in persons with schizophrenia. Current opinion in psychiatry. 2012; 25(2): 83-88.
  16. Freyberg, Z., Aslanoglou, D., Shah, R., & Ballon, J. S. Intrinsic and Antipsychotic Drug-Induced Metabolic Dysfunction in Schizophrenia. Frontiers in neuroscience. 2017 ; 11.
  17. American Psychiatric Association. Manuel diagnostique et statistique des troubles mentaux. 4ème éd. Paris : Masson; 1996.
  18. National Cholesterol Education Program Expert Panel on Detection E, Treatment of High Blood Cholesterol in A. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143-421.
  19. Mabrouk H, Mechria H, Hellara I, Ben Omrane C, Neffati F, Mechri A, et al. Profil lipidique et risque cardiovasculaire chez 121 patients schizophrènes. Immunoanal Biol Spec. 2012;27(4):159-67.
  20. Bernardo M, Canas F, Banegas JR, Casademont J, Riesgo Y, Varela C, et al. Prevalence and awareness of cardiovascular risk factors in patients with schizophrenia: a cross-sectional study in a low cardiovascular disease risk geographical area. Eur Psychiatry. 2009;24(7):431-41.
  21. Huang TL, Chen JF. Serum lipid profiles and schizophrenia: effects of conventional or atypical antipsychotic drugs in Taiwan. Schizophr Res. 2005;80(1):55-9.
  22. Wu X, Huang Z, Han H, Zhong Z, Gan Z, Guo X, et al. The comparison of glucose and lipid metabolism parameters in drug-naive, antipsychotic-treated, and antipsychotic discontinuation patients with schizophrenia. Neuropsychiatr Dis Treat. 2014;10:1361-8.
  23. Ferrieres J, Bongard V, Dallongeville J, Arveiler D, Cottel D, Haas B, et al. Trends in plasma lipids, lipoproteins and dyslipidaemias in French adults, 1996-2007. Arch Cardiovasc Dis. 2009;102(4):293-301.
  24. Kreisberg RA, Kasim S. Cholesterol metabolism and aging. Am J Med. 1987;82(1B):54-60.
  25. Matsumoto M, Tatsumi H, Murai A. Lipid metabolism and aging. Rinsho Byori.1990;38(5):530-3.
  26. Erem C, Hacihasanoglu A, Deger O, Topbas M, Hosver I, Ersoz HO, et al. Prevalence of metabolic syndrome and associated risk factors among Turkish adults: Trabzon MetS study. Endocrine. 2008;33(1):9-20.
  27. Huang T, Wu S. Serum cholesterol levels in paranoid and non-paranoid schizophrenia associated with physical violence or suicide attempts in Taiwanese. Psychiatry Res. 2000;96(2):175-8.
  28. Winkleby MA, Fortmann SP, Barrett DC. Social class disparities in risk factors for disease: eight-year prevalence patterns by level of education. Prev Med. 1990;19(1):1-12.
  29. Gupta A, Craig TK. Diet, smoking and cardiovascular risk in schizophrenia in high and low care supported housing. Epidemiol Psichiatr Soc. 2009;18(3):200-7.
  30. Haj Mouhamed D, Ezzaher A, Araoud M, Neffati F, Douki W, Najjar MF. Etude de l'activité de la paraoxonase 1 (PON1) et du profil lipidique dans une population de fumeurs tunisiens. Ann Biol clin. 2010;68(2):143-7.
  31. Schwan R, Malet L. Impact des consommations et abus d'alcool chez les sujets psychotiques. Encephale. 2007; 33(Supplement 5):192-6.
  32. Petrakis IL, Nich C, Ralevski E. Psychotic spectrum disorders and alcohol abuse: a review of pharmacotherapeutic strategies and a report on the effectiveness of naltrexone and disulfiram. Schizophr Bull. 2006;32(4):644-54.
  33. Arndt S, Tyrrell G, Flaum M, Andreasen NC. Comorbidity of substance abuse and schizophrenia: the role of pre-morbid adjustment. Psychol Med. 1992;22(2):379-88.
  34. Warner R, Taylor D, Wright J, Sloat A, Springett G, Arnold S, et al. Substance use among the mentally ill: prevalence, reasons for use, and effects on illness. Am J Orthopsychiatry. 1994;64(1):30-9.
  35. Abel EL. Effects of marihuana on the solution of anagrams, memory and appetite. Nature. 1971;231(5300):260-1.
  36. Foltin RW, Fischman MW, Byrne MF. Effects of smoked marijuana on food intake and body weight of humans living in a residential laboratory. Appetite. 1988;11(1):1-14.
  37. Wen F, Tan J. Effects of phenothiazine drugs on serum levels of apolipoproteins and lipoproteins in schizophrenic subjects. Acta Pharmacol Sin. 2003;24(10):1001-5.
  38. Wu X, Huang Z, Wu R, Zhong Z, Wei Q, Wang H, et al. The comparison of glycometabolism parameters and lipid profiles between drug-naive, firstepisode schizophrenia patients and healthy controls. Schizophr Research. 2013;150(1):157-62.
  39. Meyer JM, Nasrallah HA, McEvoy JP, Goff DC, Davis SM, Chakos M, et al. The Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE) Schizophrenia Trial: clinical comparison of subgroups with and without the metabolic syndrome. Schizophr Res. 2005;80(1):9-18.
  40. van Reedt Dortland AK, Giltay EJ, van Veen T, van Pelt J, Zitman FG, Penninx BW. Associations between serum lipids and major depressive disorder: results from the Netherlands Study of Depression and Anxiety (NESDA). J Clin psychiatry. 2010;71(6):729-36.
  41. Allison DB, Mackell JA, McDonnell DD. The impact of weight gain on quality of life among persons with schizophrenia. Psychiatr Serv. 2003;54(4):565-7. 42. Bocchetta A, Chillotti C, Carboni G, Oi A, Ponti M, Del Zompo M. Association of personal and familial suicide risk with low serum cholesterol concentration in male lithium patients. Acta Psychiatr Scand. 2001;104(1):37-41.
  42. Bocchetta A, Chillotti C, Carboni G, Oi A, Ponti M, Del Zompo M. Association of personal and familial suicide risk with low serum cholesterol concentration in male lithium patients. Acta Psychiatr Scand. 2001;104(1):37-41.
  43. Ellison LF, Morrison HI. Low serum cholesterol concentration and risk of suicide. Epidemiology. 2001;12(2):168-72.
  44. Park S, Yi KK, Na R, Lim A, Hong JP. No association between serum cholesterol and death by suicide in patients with schizophrenia, bipolar affective disorder, or major depressive disorder. Behav Brain Functs. 2013;9:45.
  45. Busner J, Targum SD. The Clinical Global Impressions Scale: Applying a Research Tool in Clinical Practice. Psychiatry (Edgmont) 2007;4(7):28-37.